Vital Heart and Vein — Cypress, Texas

Vital Heart and Vein is a clinical research site located in Cypress, Texas, United States 77429.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Vital Heart and Vein has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Peripheral Artery Disease (PAD).

Sponsors: Regeneron Pharmaceuticals.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Cypress

Browse all research sites in Texas · View every site in Cypress

• Memorial Hermann Cypress Hospital
• Houston Methodist Cypress Hospital
• Horizon Clinical Research Group
• Studies in Dermatology
• Pioneer Research Solutions
• Research Site
• GSK Investigational Site
• Northside Gastroenterology
• Clinical Research Site
• Investigational Site Number 840124
• Horizon Clinical Research Center - Houston
• Center for Clinical Studies

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Vital Heart and Vein?

Vital Heart and Vein has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Vital Heart and Vein conducted?

Vital Heart and Vein has 1 clinical trials on record, with 1 currently active. Their work covers Peripheral Artery Disease (PAD).

Is Vital Heart and Vein accredited by Crixeo Clinical Trials?

Vital Heart and Vein has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Vital Heart and Vein?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.